• Candidozyma auris in Guangzhou: Genomics and Virulence

  2026-08-13

  Wan et al. integrate whole-genome sequencing, antifungal susceptibility testing, virulence phenotyping, biofilm analysis, and a Galleria mellonella model to distinguish two prevalent Candidozyma auris clades in Guangzhou. The study links clade-specific resistance and pathogenicity traits to infection-control and antifungal-stewardship priorities, while highlighting the need to interpret genomic markers alongside phenotype.

• SB743921: Precision in Mitotic Cancer Research

  2026-08-12

  A translational framework for using SB743921 to connect selective KSP inhibition with rigorous measurements of mitotic arrest, cell death, model response, and preclinical decision-making.

• Dihydrotestosterone (DHT) in AR Signaling Workflows

  2026-08-12

  Dihydrotestosterone provides a defined androgen receptor stimulus for studying EGFR, ERBB2, AKT, and ERK responses in cancer cells. This guide translates reported DHT exposure conditions into practical assay workflows and shows how to extend them cautiously into stromal-resistance and muscle-injury models.

• Ouabain Assays: From Pump Inhibition to Cell Fate

  2026-08-11

  Ouabain is a selective Na+/K+-ATPase inhibitor whose effects extend from ion gradients to calcium handling and measurable cell fate. This guide combines mechanistic pharmacology with assay-design principles from a cancer drug-response dissertation to improve endpoint selection, timing, and interpretation.

• Allosteric PDK4 Inhibitors: Study Findings and Methods

  2026-08-10

  The reference study describes an anthraquinone-derived series of allosteric pyruvate dehydrogenase kinase 4 inhibitors and identifies compound 8c as a potent lead with activity in metabolic, allergic, and cancer-related models. Its combination of biochemical inhibition, metabolic and pharmacokinetic characterization, docking, and in vivo efficacy provides a useful framework for evaluating selective PDK4 inhibition while highlighting the limits of translating preclinical findings across disease settings.

• 10 mM dNTP Mixture for PCR and Delivery Assays

  2026-08-09

  Discover how an equimolar 10 mM dNTP mixture improves PCR, qPCR, and DNA-cargo quality control while simplifying reaction design. The workflow also shows how consistent DNA synthesis can support LNP trafficking studies without confusing upstream nucleotide quality with downstream intracellular delivery.

• MRT68921 ULK1 Kinase Inhibitor Workflow

  2026-08-08

  MRT68921 provides a mechanistic way to interrupt ULK1/2-dependent autophagy initiation while pairing naturally with ATG13 phosphorylation and LC3 flux assays. This article translates a salmon-cell lipotoxicity study into practical inhibitor workflows, controls, optimization steps, and evidence-aware experimental designs.

• Ciprofloxacin at the Nanomedicine Frontier

  2026-08-07

  Ciprofloxacin is best known as a fluoroquinolone antibiotic, yet emerging work positions it as a payload and sonosensitizer in targeted nanotheranostics. This article explains how to separate its bacterial DNA replication inhibition from ultrasound-driven tumor effects, design stronger controls, and translate the evidence without overstating preclinical findings.

• Metoprolol Tartrate: Advancing Selective β1 Blockade in Card

  2026-08-07

  Explore the unique scientific advantages of Metoprolol Tartrate as a β1-adrenergic blocking agent for cardiovascular research. This article delivers fresh insights on its mechanistic selectivity and protocol optimization, setting it apart from existing content.

• Metoprolol Tartrate: β1-Selective Blockade Beyond Cardiac Mo

  2026-08-06

  Explore the advanced scientific applications of Metoprolol Tartrate as a β1-adrenergic blocking agent in cardiovascular and hematopoietic regeneration research. This article uniquely examines the mechanistic selectivity and translational impact of β1-blockade, providing actionable insights for experimental protocols.

• Thiazovivin (A5506): Technical Guide for ROCK Inhibition Wor

  2026-08-06

  Thiazovivin is a small molecule ROCK inhibitor designed to improve the efficiency of induced pluripotent stem cell (iPSC) generation and the survival of human embryonic stem cells (hESCs) post-trypsinization. Its primary application is in stem cell research workflows where cellular viability and reprogramming efficiency are critical endpoints. Thiazovivin should not be used outside scientific research contexts or for diagnostic or medical purposes.

• Resazurin Cell Viability Assay Kit: Benchmarking Sensitivity

  2026-08-05

  Explore how the Resazurin Cell Viability Assay Kit empowers ultra-sensitive, non-toxic cell viability analysis across biological domains, with practical insights from recent oncology research. This cornerstone article uniquely bridges assay mechanism, protocol optimization, and critical findings for translational success.

• Cholesterol Impedes Lipid Nanoparticle Trafficking for DNA D

  2026-08-05

  This study reveals that elevated cholesterol content in lipid nanoparticles (LNPs) causes their entrapment in peripheral early endosomes, thereby impeding intracellular trafficking and reducing nucleic acid delivery efficiency. The findings clarify the component-specific effects of LNP formulation on endosomal escape and provide actionable insights for optimizing nonviral gene delivery strategies.

• CBX2–RACK1–HDAC1 Complex Suppresses Tumor Immunogenicity

  2026-08-04

  This study uncovers a noncanonical mechanism by which CBX2 forms a corepressor complex with RACK1 and HDAC1 to suppress interferon signaling, diminishing tumor immunogenicity and limiting immunotherapy efficacy. The findings position CBX2 as a promising target and biomarker for enhancing cancer immunotherapy response.

• Resazurin Cell Viability Assay Kit: Reliable, Sensitive Cell

  2026-08-04

  This evidence-driven guide addresses common experimental challenges in cell proliferation and cytotoxicity workflows, highlighting how the Resazurin Cell Viability Assay Kit (SKU K2234) delivers sensitive, reproducible, and non-toxic performance. Researchers will find actionable insights for protocol design, assay selection, and data interpretation in demanding biomedical contexts.

448 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page